Cancer Type
Search result for "Solr search content"
Search Result for "Esophageal cancer"
provider
Jason Gauthier, MD Cardiothoracic Surgery, Lung Transplantation, Thoracic Oncology, Esophageal Disorders
Gastrointestinal (GI) Cancer Program
Gastrointestinal (GI) Cancer Program
Clinical Trial
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic hepatocellular (HCC), biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), esophageal squamous cell carcinoma (ESCC), triple negative (TN) breast cancer (BC), hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) BC, and head and neck squamous cell carcinoma (HNSCC). The purpose of this study is to evaluate ABBV-400 in subjects with select solid tumors. This study will consist of multiple cohorts with each cohort investigating ABBV-400 at 3 mg/kg Q3W.
Lung Cancer Program
Lung Cancer Program
provider
Scott Johnson, MD Thoracic Surgery, Cardiothoracic Surgery
provider